Orchestra BioMed to Join Jefferies Global Healthcare Conference

Orchestra BioMed Holdings, Inc., a biomedical innovation company listed on Nasdaq under the ticker OBIO, has announced its participation in the upcoming Jefferies Global Healthcare Conference. This event will take place in New York, NY, from June 4-6, 2024. The company's management is set to present and engage in one-on-one meetings at the conference.

Orchestra BioMed's presentation will occur as a Fireside Chat on Wednesday, June 5, 2024, at 4:00 PM ET, Track 1. The presentation will be accessible via webcast at the provided link, with a replay available on the company's website for 90 days post-event.

The company operates under a unique business model that relies on strategic collaborations with leading medical device companies to enhance the global commercialization of its innovative products. Its prime focus is on bringing groundbreaking medical technologies to patients through risk-reward sharing partnerships.

One of Orchestra BioMed's key product candidates is the atrioventricular interval modulation (AVIM) therapy, also known as BackBeat Cardiac Neuromodulation Therapy (CNT™). This therapy targets hypertension, a critical global health issue and a significant risk factor for mortality. Additionally, the company is advancing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for treating atherosclerotic artery disease, the leading cause of death worldwide.

Orchestra BioMed has established strategic alliances to further its development and commercialization goals. It has a notable collaboration with Medtronic, one of the largest medical device companies globally, to develop and commercialize AVIM therapy for hypertension in patients requiring pacemakers. Furthermore, the company has partnered with Terumo, a global medical technology leader, for the development and commercialization of the Virtue SAB, aimed at treating artery disease.

These strategic partnerships are essential for Orchestra BioMed's mission to accelerate the delivery of high-impact medical technologies to patients and ensure successful global product launches. The company's approach underscores the importance of collaboration in the medical device industry to address significant health challenges effectively.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!